<DOC>
	<DOC>NCT01336231</DOC>
	<brief_summary>Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer</brief_summary>
	<brief_title>Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Patient (e) Age (e) over 18 years Kidney cancer metastatic or locally advanced Antiangiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together Proposed treatment in first line or second line Brain imaging not finding brain metastases Having signed the informed consent of study participation The patient may have received prior antiangiogenic Cancer of the kidney other than primitive Previous history of cancer other than kidney cancer in complete remission for less than 5 years Patients under 18 years Patients whose treatment is associated with chemotherapy disorders of cognitive functions to existing treatment delivery Pathology psychiatric evolutionary Refusal of participation Patient unable to respond to cognitive tests Drug use Heavy drinking (WHO criteria) History of stroke History of head trauma Brain metastases known MMS below normal compared to existing standards for age and sociocultural</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>quality of life</keyword>
	<keyword>cognitive functions</keyword>
	<keyword>antiangiogenic agents</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>